(Boursier.com) – The biotechnology company Pherecydes Pharma and the CEA announce the selection of the PhagECOLI project submitted within the framework of the Call for Expressions of Interest – Emerging Infectious Diseases and New Radiological Biological and Chemical Threats. This project will receive a grant from Bpifrance of 2 million euros, or 50% of its estimated cost, which will be broken down as follows: 80% for Pherecydes Pharma and 20% for CEA.
The PhagECOLI project is based on the complementary expertise and experiences of Pherecydes Pharma and CEA. This three-year project aims to provide new treatments for difficult-to-treat or resistant E. Coli infections, using precision phage therapy. In order to best meet the therapeutic need, Pherecydes Pharma and the CEA will develop a new generation of tools for measuring the effectiveness of anti-E phages. Coli on the patient’s bacterial strain. These new tools can then be the basis of a whole new generation of phagograms for the different target bacteria. This financial support will also allow Pherecydes Pharma to accelerate the development of its anti-E phages. coli.
The World Health Organization (WHO) has classified Escherichia coli in the group of bacteria presenting a critical priority in terms of finding new treatments, because of its dangerousness and its resistance to antibiotics. Resistant E. coli infections represent the most frequent infections in Europe in hospitals with more than 163,000 cases per year.
© 2022 Boursier.com